Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health

Motley Fool

Yesterday

Iovance Biotherapeutics and Teladoc Health have both sharply lagged the market. The two companies face challenges, but they are trying to turn things around. Though they are risky stocks...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2576036299"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576036299\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576036299?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837832%2Fdoctor-and-patient-in-a-hospital-room.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2025-10-17 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576036299","market":"nz","top_or_hot":-1,"title":"Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health","media":"Motley Fool","content":"<div>\n<p>Iovance Biotherapeutics and Teladoc Health have both sharply lagged the market.\n\n\n\n\n\n\n\nThe two companies face challenges, but they are trying to turn things around.\n\n\n\n\n\n\n\nThough they are risky stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2025/10/17/better-beaten-down-stock-iovance-teladoc/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-17 18:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2025/10/17/better-beaten-down-stock-iovance-teladoc/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Iovance Biotherapeutics and Teladoc Health have both sharply lagged the market.\n\n\n\n\n\n\n\nThe two companies face challenges, but they are trying to turn things around.\n\n\n\n\n\n\n\nThough they are risky stocks...</p>\n\n<a href=\"https://www.fool.com/investing/2025/10/17/better-beaten-down-stock-iovance-teladoc/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://www.fool.com/investing/2025/10/17/better-beaten-down-stock-iovance-teladoc/","article_id":"2576036299","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837832%2Fdoctor-and-patient-in-a-hospital-room.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/17/better-beaten-down-stock-iovance-teladoc/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2576036299","pubTimestamp":1760696220,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Is there a glimmer of hope for either of these underperforming healthcare companies?","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4588":"碎股","BK4167":"医疗保健技术","BK4504":"桥水持仓","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","TDOC":"Teladoc Health Inc.","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4567":"ESG概念","BK4585":"ETF&股票定投概念"},"translate_title":"更好的遭受重创的股票：Iovance Biotherapeutics与Teladoc Health","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TDOC":1.5},"content_text":"Iovance Biotherapeutics and Teladoc Health have both sharply lagged the market.\n\n\n\n\n\n\n\nThe two companies face challenges, but they are trying to turn things around.\n\n\n\n\n\n\n\nThough they are risky stocks, one of them looks a bit more attractive. \n\nHere's a great way to earn strong market returns over the long term: Identify companies that have been ignored or underestimated by most investors but have attractive prospects; buy their shares at a deep discount; and hold on to them for a long time. Picking out such corporations isn't easy, though.Let's consider two potential candidates: Iovance Biotherapeutics (IOVA -0.67%) and Teladoc Health (TDOC 0.90%). These two healthcare specialists have faced significant challenges in recent years but are trying to mount a comeback. Which one of the two is the more attractive contrarian buy? Let's find out.Image source: Getty Images.The case for Iovance BiotherapeuticsIovance Biotherapeutics is a small-cap biotech company that developed Amtagvi, a medicine for advanced melanoma. This therapy was a bit of a breakthrough, becoming the first of its kind to be approved in this indication. Amtagvi's sales have been slowly ramping up since the drug's approval in February 2024. In the first half of 2025, Iovance's revenue -- almost all of which comes from Amtagvi -- totaled $109.3 million, more than tripling compared to the year-ago period.The biotech expects revenue of $250 million to $300 million for the fiscal year, which isn't too bad for a company with a market cap of just $773 million. Further, Iovance recently received approval for Amtagvi in Canada and expects to launch the medicine in several other countries eventually. It estimates that every year, 8,000 patients in the U.S. die from melanoma. Though not all of them are eligible for Amtagvi, many more than it has treated so far are.So, between the potential in the U.S. and other regions abroad, there is an attractive market that could allow Amtagvi to eventually become a blockbuster.Lastly, Amtagvi is being investigated as a treatment for several other forms of cancer. If Iovance can make solid clinical and regulatory progress, sales of its crown jewel will grow consistently and perhaps help the company turn profitable. There are some risks. Amtagvi is a complex medicine to manufacture and administer. It is made from patients' own cells and requires 34 days (on average) to make before being inserted via intravenous infusion after they have received chemotherapy.That's why Amtagvi can only be administered in specialized centers. These are factors that somewhat limit the medicine's availability and increase commercialization expenses. But despite these challenges, if Iovance Biotherapeutics' master plan comes to fruition, the stock could soar.The case for Teladoc HealthTeladoc Health, a notable player in the telemedicine market, has lost significant traction over the past few years. However, the company's ecosystem remains deep. As of the second quarter, it had 102.4 million members in its integrated care segment, a number that grew 11% compared to the same period last year.The company's BetterHelp virtual therapy segment is bleeding paying subcribers, but the company is taking steps to address the problem. Teladoc made several acquisitions, including that of UpLift, a virtual mental health services provider. While Teladoc's own BetterHelp is not covered by insurance, UpLift has agreements with third-party payers that cover 100 million potential patients.Teladoc has long said that insurance coverage for its therapy services could help attract more people to the BetterHelp platform, which it has marketed aggressively to drum up business. Now, through UpLift, it can target its marketing efforts toward patients who already have coverage for these services but have yet to opt in.Teladoc is also betting on international expansion efforts to help turn things around. The company's international sales have been growing faster in recent quarters.Overall financial results haven't been strong. Second-quarter revenue dropped by 2% year over year to $631.9 million. But the company's well-established presence in a telemedicine market, which seems here to stay thanks to its convenience, along with efforts to boost its virtual therapy business and gain a footing abroad, might enable it to mount a comeback.Which is the better buy?To be clear, both of these companies are very risky. In my view, they are more likely than not to destroy shareholder value in the next five years. That said, Teladoc is the better option right now. It generates higher revenue and lower net losses, and has a deep ecosystem and a somewhat recognizable brand name in its industry. IOVA Revenue (Quarterly) data by YChartsIovance's Amtagvi might seem promising, but the medicine's complexity makes it hard to bet on the biotech. Chances are that if Amtagvi were commercially viable, given Iovance's terrible stock performance over the past 18 months and its market cap well under $1 billion, a larger drugmaker with deep pockets might have swooped in to acquire the whole company at its current levels.Of course, that might still happen, and there is also the chance that Amtagvi will succeed after all. Still, given the available information, contrarian investors with above-average risk tolerances should consider opting for Teladoc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}